Instil Bio
73 hedge funds and large institutions have $60.9M invested in Instil Bio in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 13 closing their positions.
1,000% more call options, than puts
Call options by funds: $11K | Put options by funds: $1K
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 77 → 73 (-4)
7.33% less ownership
Funds ownership: 78.32% → 70.99% (-7.3%)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
55% less capital inflows, than outflows
Capital inflows: $5.54M | Capital outflows: $12.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$2.98M |
| 2 |
Western Standard LLC
Los Angeles,
California
|
+$1.33M |
| 3 |
Millennium Management
New York
|
+$380K |
| 4 |
Two Sigma Advisers
New York
|
+$282K |
| 5 |
Tang Capital Management
San Diego,
California
|
+$148K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.06M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$869K |
| 3 |
Squarepoint
New York
|
-$370K |
| 4 |
Renaissance Technologies
New York
|
-$345K |
| 5 |
6CM
683 Capital Management
New York
|
-$343K |
TIL Hedge Fund Activity: Q1 2023 in Review
73 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q1 2023, worth a combined $60.9M — down 4.9% from $64M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TIL and 9 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 23 added.
The largest buyer was Citigroup, adding an estimated $2.98M. The largest seller was Fidelity Investments, cutting an estimated $9.06M.
- 73 institutional investors held Instil Bio (TIL) as of Q1 2023, down from 77 in Q4 2022.
- Funds reported $60.9M of Instil Bio stock for Q1 2023, down 4.9% quarter-over-quarter.
- 9 funds opened new Instil Bio positions in Q1 2023 and 13 closed out, a net change of -4 holders.
- The largest Instil Bio buyer in Q1 2023 was Citigroup, an estimated $2.98M added.
- The largest Instil Bio seller in Q1 2023 was Fidelity Investments, an estimated $9.06M sold.
Based on aggregated 13F filings for Q1 2023.